Can If inhibition help in congestive heart failure?

Dialogues in Cardiovascular Medicine

Volumn 11, Issue 1, 2006, Pages 30-35

  Tavazzi, Luigi ^a   Mugelli, Alessandro ^b  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Electrophysiological remodeling; Electrophysiology; Heart failure; Heart rate; If inhibition; Ivabradine; Ventricular myocyte

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CARVEDILOL; COLLAGEN; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; HYDRALAZINE; HYPOCHOLESTEROLEMIC AGENT; IVABRADINE; METOPROLOL; NITRATE; PHOSPHODIESTERASE INHIBITOR; PLACEBO; POTASSIUM CHANNEL; POTASSIUM CHANNEL BLOCKING AGENT; PRAZOSIN; TIMOLOL; XAMOTEROL;

ANGINA PECTORIS; AREA UNDER THE CURVE; ARTICLE; CAPILLARY DENSITY; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DISEASE MODEL; DIZZINESS; DOG; DRUG CONTRAINDICATION; DRUG SELECTIVITY; DRUG WITHDRAWAL; DYSPNEA; EVIDENCE BASED MEDICINE; FATIGUE; HEART ARRHYTHMIA; HEART FAILURE; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE CELL; HEART RATE; HEART VENTRICLE REMODELING; HEART VENTRICLE WALL; HEART WORK; HOSPITALIZATION; HUMAN; HYPOTENSION; HYPOTHESIS; INOTROPISM; MORTALITY; NONHUMAN; POTASSIUM CURRENT; RAT; SINUS NODE; SURVIVAL RATE; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME;

EID: 33744536301     PISSN: 12729949     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. f inhibitor in stable angina: a randomized, double blinded, multicenter, placebo-controlled trail. Circulation. 2003;107:817-823.
2. Kjekshus J, Gullestad L. Heart rate as a therapeutic target in heart failure. Eur Heart J. 1999;1(suppl H):H64-H69.
3. Swedberg K, Eneroth P, Kjekshus J, et al. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group. Circulation. 1990;82:1730-1736.
4. Nul DR, Doval HC, Grancelli HO, et al; GESICA-GEMA Investigators. Heart rate is a marker of amiodarone mortality reduction in severe heart failure. J Am Coll Cardiol. 1997;29:1199-1205.
5. Nagatsu M, Spinale FG, Koide M, et al. Bradycardia and the role of beta-blockade in the amelioration of left ventricular dysfunction. Circulation. 2000;101:653-659.
6. Wikstrand J, Hjalmarson A, Waagstein F, et al. Dose of metoprolol CR/KL and clinical outcomes in patients with heart failure. J Am Call Cardiol. 2002;40:491-498
7. Lechat P, Hulot JS, Escolano S, et al. Heart rate and cardiac rhythm relationships with bisoprolol benefit in chronic heart failure in CIBIS II trial. Circulation. 2001;103:1428-1433.
8. Unverferth DV, Magorien RD, Lewis RP, et al. The role of subendocardial ischemia in perpetuating myocardial failure in patients with non-ischemic congestive cardiomyopathy. Am Heart J. 1983:105:176-179.
9. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. US Carvedilol Heart Failure Study Group. N Engl J Med. 1996;334:1349-1355.
10. Arnold RH, Kotlyar E, Hayward C, et al. Relation between heart rate, heart rhythm, and reverse left ventricular remodelling in response to carvedilol in patients with chronic heart failure: a single centre, observational study. Heart. 2003;89:293-298.
11. f current inhibitor ivabradine improves left ventricular function and intrinsic myocardial structure in congestive heart failure. Circulation. 2004;109:1674-1679.
12. Jondeau G, Korewicki J, Vasillanskas D. Effect of ivabradine in patients with left ventricular systolic dysfunction and coronary artery disease. Eur Heart J. 2004;25(suppl):451. Abstract 2637.
13. Pharmacokinetics of Ivabradine. Summary of Product Characteristics. London, UK: EMEA; 25 October 2005.
14. Gupta R, Wilson Tang WH, Young JB. Patterns of beta-blocker utilization in patients with chronic heart failure: experience from a specialized outpatient heart failure clinic. Am Heart J. 2004;147:79-83.
15. Maggioni AP, Sinagra G, Opasich C, et al. Treatment of chronic heart failure with beta andrenergic blockade beyond controlled clinical trials: the BRING-UP experience. Heart. 2003;89:299-305.
16. Sin DD, Mc Alister FA. The effects of beta-blockers on morbidity and mortality in a population-based cohort of 11,942 elderly patients with heart failure. Am J Med. 2002; 113:650-656.
17. Di Lenarda A, Scherillo M, Maggioni, et al; TEMISTOCLE Investigators. Current presentation and management of heart failure in cardiology and internal medicine hospital units: a tale of two worlds. The TEMISTOCLE study. Am Heart J. 2003;146:e12.
18. Noma A, Irisawa H. Membrane currents in the rabbit sinoatrial node cell as studied by the double micro-electrode method. Pflugers Arch. 1976;364:45-52.
19. Brown HF, DiFrancesco D, Noble SJ. How does adrenaline accelerate the heart? Nature. 1979;280:235-236.
20. Yu H, Chang F, Cohen IS. Pacemaker current exists in ventricular myocytes. Circ Res. 1993;72:232-236.
21. f, in ventricular myocytes isolated from hypertensive rats. J Physiol (Lond). 1994; 481:585-591.
22. f in ventricular myocytes from normotensive and hypertensive rats during aging. Circulation. 1996;94:1674-1681.
23. Stilli D, Sgoifo A, Macchi E, et al. Myocardial remodeling and arrhythmogenesis in moderate cardiac hypertrophy in rats. Am J Physiol-Heart Circ Physiol. 2001;280:H142-H150.
24. Barbieri M, Varani K, Cerbai E, et al. Electrophysiological basis for the enhanced cardiac arrhythmogenic effect of isoprenaline in aged spontaneously hypertensive rats. J Mol Cell Cardiol. 1994;26:849-860.
25. f) and hyperpolarization-activated cyclic nucleotide-gated channel mRNA expression in ventricular cells from control and hypertrophied rat hearts. J Physiol (Lond). 2003;553:395-405.
26. Sartiani L, Cerbai E, DePaoli P, et al. The expression and pharmacological modulation of the pacemaker current in ventricular myocytes from post myocardial infarction. Circulation. 2000;102:129.
27. Biel M, Schneider A, Wahl C. Cardiac HCN channels: structure, function, and modulation. Trends Cardiovasc Med. 2002;12:206-213.
28. Shi W, Wymore R, Yu H, et al. Distribution and prevalence of hyperpolarization-activated cation channel (HCN) mRNA expression in cardiac tissues. Circ Res. 1999;85:el-e6.
29. Accili EA, Proenza C, Baruscotti M, DiFrancesco D. From funny current to HCN channels: 20 years of excitation. News Physiol Sci. 2002;17:32-37.
30. f occurrence and properties in neonatal rat ventricular myocytes. Cardiovasc Res. 1999;42:416-423.
31. f current and spontaneous activity in mouse embryonic ventricular myocytes. Circ Res. 2001; 88:536-542.
32. f, in ventricular myocytes from human failing heart. Circulation. 1997;95:568-571.
33. Hoppe UC, Jansen E, Sudkamp M, Beuckelmann DJ. Hyperpolarization-activated inward current in ventricular myocytes from normal and failing human hearts. Circulation. 1998;97:55-65.
34. f in human ventricular myocytes are modulated by cardiac disease. J Mol Cell Cardiol. 2001;33:441-448.
35. f) in normal and failing human heart. Circulation. 2004;110(suppl)III129.
36. Cerbai E, Crucitti A, Sartiani L, et al. Long-term treatment of spontaneously hypertensive rats with losartan and electrophysiological remodeling of cardiac myocytes. Cardiovasc Res. 2000;45:388-396.
37. Cerbai E, De Paoli P, Sartiani L, Lonardo G, Mugelli A. Treatment with irbesartan counteracts the functional remodeling of ventricular myocytes from hypertensive rats. Cardiovasc Pharmacol. 2003;41:804-812.